AGING CELL:阿尔兹海默相关蛋白是1型糖尿病认知缺陷的基础

2019-03-01 海北 MedSci原创

糖尿病(DM)是目前影响人口老龄化的最具破坏性的疾病之一。最近的证据表明,由于其对认知的直接影响,DM是许多脑部疾病的风险因素。

糖尿病(DM)是目前影响人口老龄化的最具破坏性的疾病之一。最近的证据表明,由于其对认知的直接影响,DM是许多脑部疾病的风险因素。

还有新发现表明,微管相关蛋白tau在DM患者中会进行病理学修饰。然而,至今为止,病理性tau修饰是否在与DM相关的认知缺陷中发挥核心作用尚不清楚。

为了解决这个问题,研究人员使用功能获得和功能丧失的方法来调节1型糖尿病(T1DM)和2型糖尿病(T2DM)小鼠模型中的tau水平。

该研究表明,tau差异性地促成DM诱导的认知和突触缺陷。一方面,过表达野生型人类tau进一步加剧了由T1DM诱导的认知和突触损伤,因为在T1DM条件下,人tau处理的小鼠在学习和记忆过程中表现出强烈的缺陷。

另一方面,tau水平的降低和增加均不影响T2DM小鼠的认知。

总之,这些结果为与T1DM和T2DM相关的认知和突触损伤的不同分子机制提供了新的亮点。


原始出处:

Laura Trujillo‐Estrada et al. Tau underlies synaptic and cognitive deficits for type 1, but not type 2 diabetes mouse models. Aging Cell, 2019; doi: https://doi.org/10.1111/acel.12919


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1961455, encodeId=6d11196145598, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 10 19:18:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871177, encodeId=a1b918e117733, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 15 07:18:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402777, encodeId=6a6a1402e778f, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Mar 02 23:18:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042287, encodeId=8c78104228eff, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Mar 01 11:18:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-09-10 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1961455, encodeId=6d11196145598, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 10 19:18:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871177, encodeId=a1b918e117733, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 15 07:18:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402777, encodeId=6a6a1402e778f, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Mar 02 23:18:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042287, encodeId=8c78104228eff, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Mar 01 11:18:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1961455, encodeId=6d11196145598, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 10 19:18:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871177, encodeId=a1b918e117733, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 15 07:18:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402777, encodeId=6a6a1402e778f, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Mar 02 23:18:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042287, encodeId=8c78104228eff, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Mar 01 11:18:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1961455, encodeId=6d11196145598, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 10 19:18:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871177, encodeId=a1b918e117733, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 15 07:18:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402777, encodeId=6a6a1402e778f, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Mar 02 23:18:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042287, encodeId=8c78104228eff, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Mar 01 11:18:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-03-01 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

NSR: 中国阿尔茨海默氏症有“共同”风险基因

分析提示,相对于非风险变异携带者,rs3792646风险变异携带者可能在20岁左右就出现大脑海马体积小与工作记忆能力弱的表现。

Nature Neuroscience:不断接近的阿尔兹海默真相

科学家们正在研究免疫细胞激活在阿尔茨海默病中的作用,最新Nature Neuroscience文章表明,大脑中有缺陷的免疫细胞会导致阿尔茨海默病。

NEURON:纤维蛋白原诱导阿尔茨海默病的认知障碍

至今为止,关于血管损伤是否有助于突触功能障碍,以及它如何与淀粉样蛋白病理学协同作用引起神经炎症和认知能力下降,我们仍然知之甚少。

JAMA:控制血压能降低阿尔茨海默症风险?

轻度认知障碍(MCI)是指比同龄人在认知、思考、记忆和推理方面更困难,是阿尔茨海默症的先兆。阿尔茨海默症是一种更为严重的认知功能丧失,它会影响日常生活,仍然是一个巨大的公共卫生挑战。目前还没有有效的治疗方法来降低轻度认知障碍和阿尔茨海默症的风险。

AGING CELL:研究人员发现改善阿尔茨海默病树突异常的途径

研究人员在许多神经退行性疾病中发现了树突树和树突脊的损伤,包括阿尔茨海默氏病(AD)。已有的研究还显示,AD中具有褪黑激素信号通路的缺陷。褪黑激素受体2(MT2)在海马中广泛表达,并介导褪黑激素的生物学功能。

NAT MED:运动如何预防阿尔茨海默氏症?

最近,研究人员发现,AD海马和脑脊液中的FNDC5 /鸢尾素水平降低,在实验AD模型中也一致。